Impact of a lopinavir/ritonavir (Kaletra) based second-line antiretroviral therapy regimen on lipid and lipoprotein profiles in an African setting.

Abstract

Background: Most resource-constrained countries reserve boosted proteinase inhibitors (PIs) for second-line treatment following WHO recommendations. Lipid profiles at first-line clinical/immunological failure and following PI-based second-line treatment have not been studied in Africa. Methods: DART is a randomized trial comparing HIV/AIDS management strategies in Uganda/Zimbabwe in adults initiating first-line ART and switching to LPV/r-containing second-line treatment at clinical failure (WHO 4) or, in those randomised to laboratory monitoring, at immunological failure. We evaluated fasting lipid profiles at second-line initiation and 48 weeks subsequently in stored samples from patients in Zimbabwe remaining on LPV/r for >48 weeks. Results: 91 patients switched to second-line before 18 September 2006, of whom 66 (73%) had fasting samples at switch and 48 weeks, 14 (15%) died/were lost to follow-up 14 days and 1 (1%) had no samples available. Of the 66 patients included (34 male), 57 (86%) received ZDV/d4T+3TC+TDF first-line, 6 (9%) ZDV/d4T+3TC+NVP, and 3 (5%) ZDV+3TC with TDF and NVP. Initial second-line treatment was NNRTI+LPV/r in 27 (41%), ddI+NNRTI+LPV/r in 33 (50%) and LPV/r+TDF+ddI/3TC/ZDV in the remaining 6 (9%). At second-line initiation median (interquartile range) total cholesterol, LDL, HDL and vLDL cholesterol (in mmol/lire) were 3.3 (2.9-4.2), 1.8 (1.5-2.3), 0.7 (0.6-0.8) and 0.7 (0.6-1.1) respectively, with triglycerides 1.0 (0.7-1.8). Levels were significantly increased after 48 weeks of LPV/r-containing second-line, by mean (standard error) +2.0 (0.1), +1.1 (0.1), +0.5 (0.05) and +0.5( 0.05) respectively (all p7.8 mmol/L) and grade 2 LDL-C (4.1-4.9 mmol/L); no triglycerides were elevated, but 81% had HDL-C

Citation

Gomo, Z.; Walker, Z.; Hakim, J.; Reid, A.; Munderi, P.; Kityo, C.; Gibb, D.; Gilks, C.; Musarurwa, C.; DART Trial team. Impact of a lopinavir/ritonavir (Kaletra) based second-line antiretroviral therapy regimen on lipid and lipoprotein profiles in an African setting. Presented at AIDS 2008 – XVII International AIDS Conference, Mexico City, Mexico, 3-8 August 2008. (2008)

Impact of a lopinavir/ritonavir (Kaletra) based second-line antiretroviral therapy regimen on lipid and lipoprotein profiles in an African setting.

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.